Multicenter Prospective Randomized Phase II/III Study of Neoadjuvant Chemoradiation With Gemcitabine in Patients With Borderline Resectable Pancreatic Cancer
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
2-year survival rate
2-year actual survival outcome
No
Jin-Young Jang, M.D., Ph.D.
Principal Investigator
Seoul National University College of Medicine
Korea: Institutional Review Board
BorderlinePancreas
NCT01458717
November 2011
December 2016
Name | Location |
---|